![]() |
Name |
(3S,4S,5R,7S,9R,10S,13S,17S,19S,23R,30R)-5,7,11,13,14,16-hexamethyl-2-oxa-21-azaheptacyclo[23.2.2.13,10.04,9.012,16.019,23.017,30]triaconta-1(28),11,14,25(29),26-pentaene-18,20,22-trione
|
Molecular Formula | C34H41NO4 | |
IUPAC Name* |
(3S,4S,5R,7S,9R,10S,13S,17S,19S,23R,30R)-5,7,11,13,14,16-hexamethyl-2-oxa-21-azaheptacyclo[23.2.2.13,10.04,9.012,16.019,23.017,30]triaconta-1(28),11,14,25(29),26-pentaene-18,20,22-trione
|
|
SMILES |
C[C@H]1C[C@H]([C@H]2[C@H](C1)[C@H]3[C@H]4[C@H]2OC5=CC=C(C[C@@H]6[C@@H](C(=O)[C@@H]4C7(C=C([C@@H](C7=C3C)C)C)C)C(=O)NC6=O)C=C5)C
|
|
InChI |
InChI=1S/C34H41NO4/c1-15-11-16(2)24-22(12-15)25-19(5)28-18(4)17(3)14-34(28,6)29-27(25)31(24)39-21-9-7-20(8-10-21)13-23-26(30(29)36)33(38)35-32(23)37/h7-10,14-16,18,22-27,29,31H,11-13H2,1-6H3,(H,35,37,38)/t15-,16+,18-,22-,23+,24-,25-,26-,27+,29+,31-,34?/m0/s1
|
|
InChIKey |
UKJXAQYJWFBJPH-TYZAYTANSA-N
|
|
Synonyms |
Phomapyrrolidone A
|
|
CAS | NA | |
PubChem CID | 102228810 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 527.7 | ALogp: | 5.6 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 72.5 | Aromatic Rings: | 8 |
Heavy Atoms: | 39 | QED Weighted: | 0.266 |
Caco-2 Permeability: | -5.13 | MDCK Permeability: | 0.00001610 |
Pgp-inhibitor: | 0.967 | Pgp-substrate: | 0.982 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.014 |
30% Bioavailability (F30%): | 0.011 |
Blood-Brain-Barrier Penetration (BBB): | 0.009 | Plasma Protein Binding (PPB): | 100.53% |
Volume Distribution (VD): | 2.435 | Fu: | 1.24% |
CYP1A2-inhibitor: | 0.148 | CYP1A2-substrate: | 0.761 |
CYP2C19-inhibitor: | 0.798 | CYP2C19-substrate: | 0.591 |
CYP2C9-inhibitor: | 0.797 | CYP2C9-substrate: | 0.966 |
CYP2D6-inhibitor: | 0.832 | CYP2D6-substrate: | 0.406 |
CYP3A4-inhibitor: | 0.904 | CYP3A4-substrate: | 0.788 |
Clearance (CL): | 9.595 | Half-life (T1/2): | 0.005 |
hERG Blockers: | 0.116 | Human Hepatotoxicity (H-HT): | 0.86 |
Drug-inuced Liver Injury (DILI): | 0.979 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.974 | Maximum Recommended Daily Dose: | 0.972 |
Skin Sensitization: | 0.095 | Carcinogencity: | 0.204 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.971 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003773 | ![]() |
1.000 | D07DIM | ![]() |
0.232 | ||
ENC005366 | ![]() |
0.672 | D06XZW | ![]() |
0.220 | ||
ENC003606 | ![]() |
0.672 | D03LJR | ![]() |
0.218 | ||
ENC003503 | ![]() |
0.591 | D09HNR | ![]() |
0.215 | ||
ENC005365 | ![]() |
0.484 | D01UBX | ![]() |
0.214 | ||
ENC005770 | ![]() |
0.447 | D0TG7I | ![]() |
0.213 | ||
ENC005769 | ![]() |
0.437 | D0VA0I | ![]() |
0.213 | ||
ENC003349 | ![]() |
0.425 | D0FX2Q | ![]() |
0.211 | ||
ENC005135 | ![]() |
0.418 | D0K3QS | ![]() |
0.210 | ||
ENC005766 | ![]() |
0.418 | D0V7WS | ![]() |
0.206 |